Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD56-enriched donor lymphocyte infusion
- Development stage
- Phase 1
- Lead developer
- City of Hope
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD56-enriched donor lymphocyte infusion (DLI) is an adoptive cell therapy consisting of donor-derived lymphocytes that have been processed to enrich for CD56-positive cells, primarily Natural Killer (NK) cells. This intervention is typically administered following allogeneic hematopoietic stem cell transplantation (HSCT), particularly in the haploidentical setting, to enhance the graft-versus-leukemia (GVL) effect and prevent disease relapse. By selecting for CD56+ cells and potentially depleting T cells, the therapy aims to provide potent anti-tumor activity while reducing the risk of graft-versus-host disease (GVHD) compared to conventional unmanipulated donor lymphocyte infusions. The enrichment is often achieved using automated immunomagnetic selection systems.
- Other names
- CD56-enriched DLICD-56-enriched DLICD 56-enriched DLICD56+ enriched donor lymphocyte infusionCD56-selected donor lymphocyte infusionCD-56-selected donor lymphocyte infusionCD 56-selected donor lymphocyte infusion
Beyond the preview
Go deeper on CD56-enriched donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD56-enriched donor lymphocyte infusion.